The X-Change Corporation Lifted by Dr. Sanjay Gupta, CNN Chief Medical Correspondent, Mainstream CNN Media Article Objectively Addressing Treatment Benefits of Cannabinoids For Life Threatening Conditions After a Year of Study, Dr. Gupta Changes His Mind and Declares His Support for Patient Access to Medical Cannabis

COLORADO SPRINGS, Colo., Aug. 9, 2013 /PRNewswire/ -- The X-Change Corporation (NASDAQ OTC: XCHC), a U.S. Company specializing in cannabinoid formulation-based health and wellness solutions, commends CNN's Dr. Sanjay Gupta's reporting on the life saving medical cannabis treatment of child with a severe seizure syndrome. CNN's coverage is the inspiring life-saving story of a child with Dravet Syndrome, also known as severe myoclonic epilepsy of infancy (SMEI), who nearly died from 5 years of seizures and ineffective and damaging conventional treatments. 

After a year-long study of medical cannabis and first-hand observation of patient outcomes, such as the seizure patient just described, CNN's Dr. Gupta, a renowned neurosurgeon and medical commentator, publicly announced in an editorial published yesterday that he has reversed his position and now supports patient use of medical cannabis.

"Why I Changed my Mind on Weed"
By Dr. Sanjay Gupta, CNN Chief Medical Correspondent
August 9, 2013 -- Updated 0044 GMT (0844 HKT) :
http://edition.cnn.com/2013/08/08/health/gupta-changed-mind-marijuana/index.html

Dr. Gupta notes that "[we] have been terribly and systematically misled [about medical cannabis] for nearly 70 years in the United States, and I apologize for my own role in that," citing a contrary article Dr. Gupta wrote only four years ago for Time magazine.  Dr. Gupta continues in his editorial: "... I didn't look hard enough, until now. I didn't look far enough. I didn't review papers from smaller labs in other countries doing some remarkable research, and I was too dismissive of the loud chorus of legitimate patients whose symptoms improved on cannabis."

The young child reached the point where she could no longer talk, walk, or eat.  With little hope of her survival, the young girl's parents learned that medical cannabis might provide a solution.  Despite initial skepticism, under appropriate physician care afforded by evolving laws, the parents and doctors proceeded with treatment.  As reported, the first dose of cannabis oil immediately reduced the monthly incidence of their daughter's grand mal seizures from more than 1,200 to 2 or 3.  Further, with a continuing regimen of medical cannabis oil treatment, their daughter's mental and physiological damage has abated, and she is regaining verbal skills, feeding herself, and riding her bicycle.

Please visit:  http://www.cnn.com/2013/08/07/health/charlotte-child-medical-marijuana/index.html?hpt=hp_t1

Dr. Dorothy Bray, President of The X-Change Corporation, said, "As increasing numbers of researchers, physicians, and politicians line up behind the effective, compassionate use of cannabinoid-based treatments, the Company's research and commercial development programs continue to move forward with confidence."

About The X-Change Corporation
The X-Change Corporation is currently developing new natural cannabinoid containing products based on innovative formulations to utilize the unique and potent benefits of the cannabis and hemp plants. Medicinal properties of cannabis and hemp have been known and applied for thousands of years. With the aid of scientific research, The X-Change Corporation is translating such knowledge into development of effective cannabinoid formulation-based health and wellness solutions as well as cosmeceutical, nutraceutical, and food brands throughout the world. The Company's health and wellness, nutritional, and cosmetics lines will address personal needs and will evolve with the introduction of new formulations and products, advancing the Company within the expanding multibillion-dollar global market.

Forward Looking Statements
This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing works such as "anticipate," "seek," intend," "believe," "plan," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based solutions. X-Change Corp. does not undertake any duty nor does it intend to update the results of these forward-looking statements.

The X-Change Corporation

Dr. Dorothy Bray, President
info@xchangecorp.com
www.xchangecorp.com
+1.866.326.5595

Investment Inquiries
Robert Kane
CFO, Sr Vp of Business Development
rkane@xchangecorp.com
+1.561.420.4824

SOURCE The X-Change Corporation



RELATED LINKS
http://www.xchangecorp.com

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.